The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors

A multicenter retrospective study in Japan

Akira Sakamaki, MD, PhD^a, Kenya Kamimura, MD, PhD^ab, Takeshi Yokoo, MD, PhD^b, Akihiko Osaki, MD, PhD^b, Seiichi Yoshikawa, MD, PhD^b, Yoshihisa Arao, MD^a, Toru Setsu, MD, PhD^b, Hiroteru Kamimura, MD, PhD^c, Nobuo Waguri, MD, PhD^b, Manabu Takeuchi, MD, PhD^c, Kazuhiro Funakoshi, MD, PhD^d, Shuji Terai, MD, PhD^a

Abstract
Gastrointestinal bleeding, hepatic encephalopathy (HE), and hepatocarcinogenesis are associated with the prognosis of patients with liver cirrhosis (LC). Proton pump inhibitors (PPIs) have been used to prevent bleeding, however the effects of PPIs on overall survival have not yet been elucidated. Therefore, this multicenter retrospective study aimed to assess the effect of PPI on the prognosis and HE occurrence of the patients with liver cirrhosis in Japan.

A total of 456 patients diagnosed with LC at the 4 institutes during the study period (2010–2014) were assessed. PPI-treated and non-treated patients were compared using propensity score matching analysis. Primary and secondary endpoints of the study were set as the occurrence of HE and overall survival, respectively.

A comparison of all cases showed a significantly poorer hepatic reserve function in the PPI-treated patients. The propensity-score matching analysis was performed and 120 PPI-treated patients were 1:1 matched with non-treated patients. The analysis revealed a higher incidence of HE in the PPI-treated than in the non-treated patients (P= .032; hazard ratio [HR], 2.162; 95% confidence interval [CI], 1.066–4.176), but the prognosis of PPI-treated patients was no worse than that of non-treated patients (P= .676; HR, 1.101; 95% CI, 0.702–1.726).

This retrospective study showed that PPI administration for the patients with liver cirrhosis may partly be related to the increased incidence of HE but not worsen the patient prognosis.

Abbreviations: GI = gastrointestinal, HCC = hepatocellular carcinoma, HE = hepatic encephalopathy, LC = liver cirrhosis, PPIs = proton pump inhibitors.

Keywords: gastrointestinal bleeding, hepatic encephalopathy, liver cirrhosis, prognosis, proton pump inhibitor

1. Introduction
Liver cirrhosis (LC) is the end-stage of chronic liver disease, and has a median survival time of 33 months. Gastrointestinal (GI) bleeding, hepatic encephalopathy (HE), and hepatocarcinogenesis are the leading causes of poor prognosis in LC patients.[1] Among them, the occurrence of HE is related to several factors, including an aberrance in gut bacteria, such as dysbiosis and small intestine bacterial overgrowth, which could precipitate bacterial translocation,[2–4] and GI bleeding, which triggers the increase of nitrogen compounds due to blood in the gut.[5] Management of GI bleeding is therefore essential.[6] Proton pump inhibitors (PPIs) have been used for treating ulcerative lesions[7] and variceal lesions,[8,9] and have shown efficacy in preventing the recurrence of bleeding. In addition, a recent randomized placebo-controlled trial including 17,598 patients, showed that there was no association between pantoprazole and any adverse events, except for an increased risk of enteric infections, over a three-year period.[10] On the other hand, HE and PPI administration have been reported to be related[11] and Nardelli et al, assessing 310 patients in Italy, reported an association between PPI and minimal HE, overt HE, and mortality.[12] In this study, we assessed 456 patients with liver cirrhosis using propensity score matching to confirm the relation between PPI and HE occurrence and the prognosis in a Japanese cohort.
2. Materials and methods

2.1. Data collection and inclusion and exclusion criteria

This multicenter retrospective study was performed in the Niigata Prefecture of Japan, and data were collected from 4 hospitals: Nagaoka Red Cross Hospital, Niigata Central Prefectural Hospital, Niigata City General Hospital, and Niigata University Hospital. The study was approved by the ethical review board of Niigata University (Number 2018–0193). We collected data from hospital medical records of patients diagnosed with LC between January 2010 and December 2014 followed by the mean observation period of 3.1 ± 1.4 years. LC diagnosis was based on clinical evidence, such as chronic changes in liver and spleen morphology, demonstrated by imaging, with thrombocytopenia, HE, and esophagogastric varices. Patients with a history of hepatocellular carcinoma (HCC) were included if they showed no recurrence for more than 3 years after the last treatment. The PPI-treated group had PPI administered for more than 6 weeks at the time of inclusion. Patients with secondary liver dysfunction, including those with hepatic congestion and metastatic liver tumors, were excluded. A total of 672 patients satisfied the study criteria, including 111, 130, 177, and 254 patients from Nagaoka Red Cross Hospital, Niigata Central Prefectural Hospital, Niigata City General Hospital, and Niigata University Hospital, respectively.

Among the 672 patients, 77 patients who lacked laboratory and/or imaging findings after the first 6 months, 20 patients who had a history of liver transplantation, and 119 patients who had intermittent PPI administration during the study period were excluded. The remaining 456 patients were assessed in the final analyses and PPI-treated and non-treated groups were defined as patients who were and were not treated with PPIs for the entire study period, respectively. Fig. 1 summarizes the patient selection process. The primary study endpoint was set as the incidence of a new occurrence of HE during the observation period, and the secondary study endpoint was set as overall survival. Onset of HE was defined as overt HE symptoms (≥grade 2)\(^{[13]}\) with treatment intervention including intravenous branched-chain amino acid infusions.

2.2. Statistical analysis

The PPI-treated and non-treated patient groups were compared using propensity-score matching analysis with adjusting factors including age; sex; background hepatitis (alcoholic hepatitis or viral and alcoholic combined hepatitis); observation period; presence of HCC; presence of GI bleeding (meaning the events of GI bleeding from the gastroesophageal varices, gastroduodenal ulcers, Mallory-Weiss syndrome, and angiodysplasia over the entire study period); prior interventional therapy for varices, including endoscopic injection sclerotherapy (EVL), balloon-occluded retrograde transvenous obliteration (BRTO), and surgery; advanced cirrhosis state (a Child–Pugh score of ≥7 or treatment for complications of LC, including loop diuretics, branched-chain amino acids, synthetic disaccharides, and poorly absorbable oral antibiotics). The Kolmogorov–Smirnov test was used to assess the normality of the distribution of continuous variables. Wilcoxon signed-rank sum and Fisher exact tests were used to compare data at the study entry point, and the cumulative incidence plots method with the log-rank test was used to

---

**Figure 1.** The patient selection process for the multicenter retrospective study to determine the effects of proton pump inhibitors for gastric bleeding on the incidence of hepatic encephalopathy and prognosis in patients with liver cirrhosis. LC = liver cirrhosis, PPI = proton pump inhibitor.

---
3. Results

The study cohort included 279 males and 177 females, with an average age of 66.8 ± 11.3 years. PPI treatment was used in 195 patients (42.8%). Table 1 shows the rate of PPIs. Rabeprazole was the most frequently used PPI (51.3%), followed by lansoprazole, omeprazole, and esomeprazole. The mean observation period in the entire cohort was 3.1 ± 1.4 years. Furthermore, 63 patients (13.8%) had HE as a complication, and 122 (26.8%) died during the study period. A simple comparison of PPI-treated and non-treated patients showed statistical differences in: age (younger in PPI-treated, \( P < .001 \)), Child-Pugh scores (higher in PPI-treated, \( P = .001 \)), model for end-stage liver disease scores (higher in PPI-treated, \( P = .005 \)), onset of HE (higher in PPI-treated, \( P = .017 \)), and onset of GI bleeding (higher in PPI-treated, \( P < .001 \)), however there was no difference in hepatocarcinogenesis (\( P = .523 \)) (Table 2). To further analyze the actual effects of PPI on the prevention of HE occurrence, the 2 groups were compared using propensity score matching analysis after adjusting for factors including age, sex, background hepatitis, observation period, presence of HCC, presence of GI bleeding, prior history of interventional therapy for varices, and advanced cirrhosis state (see materials and methods section for the details). One hundred twenty PPI treated and non-treated patients were 1:1 matched and no significant differences were found between the 2 groups in terms of age, sex, background hepatitis, liver function, kidney function, and complication of HCC and GI bleeding (Table 3).

The incidence of HE was higher among PPI-treated than PPI non-treated patients (\( \chi^2 = .032; \) hazard ratio [HR], 2.162; 95% confidence interval [CI], 1.066–4.176; Fig. 2a). In addition, in subgroup analyses among the PPI-treated patients, rabeprazole was associated with fewer HE cases than other PPIs (3 groups, \( \chi^2 = .007; \) rabeprazole vs other PPIs, \( \chi^2 = .001 \)). Interestingly, although the HE increased in the PPI-treated group in our study cohort, PPIs were not associated with worsen prognoses (five-year survival rate, 52.4% vs 54.5%; \( \chi^2 = .676; \) HR, 1.101; 95% CI, 0.702–1.726; 5-year incidence rates of GI bleeding, % 19.2 \( < .001 \); other PPIs vs PPI treated, \( \chi^2 = .001 \)).

Table 1

| PPI                        | n (%)  |
|----------------------------|--------|
| Rabeprazole                | 100 (61.3) |
| Lansoprazole               | 52 (26.7) |
| Omeprazole                 | 15 (7.7) |
| Esomeprazole               | 11 (5.6) |
| Several types              | 17 (8.7) |

PPI = proton pump inhibitor.

Table 2

| Groups | Age, yrs (mean ± SD) | Gender, n (%) | Background hepatitis, n (%) | Hepatitis B | Hepatitis C | Alcoholic hepatitis | Others | Total bilirubin, mg/dL | Prothrombin time, % | Albumin, g/dL | Creatinine, mg/dL | Child-Pugh Score | MELD score | Agents for LC complications, n (%) | Loop diuretics, n (%) | Synthetic disaccharides, n (%) | Oral poorly absorbable antibiotics, n (%) | LC statement, n (%) | 5-year incidence rate of HCC, % | 5-year incidence rate of HE, % | 5-year incidence rate of GI bleeding, % | Observation period, years (mean ± SD) | 5-year survival rate, % |
|--------|---------------------|---------------|-----------------------------|-------------|-------------|---------------------|--------|------------------------|---------------------|--------------|----------------|----------------|----------|-----------------------------------|-----------------------|-----------------------------|---------------------------------|-------------------|-------------------------------|----------------------|-------------------------------|--------------------------|-------------------------|
| PPI treated N = 195 | 64.6 ± 11.1 | .654 | .565 | 18 (9.2) | 58 (29.7) | 69 (35.4) | 50 (25.7) | 1.6 ± 1.7 | 73.6 ± 18.2 | 3.5 ± 0.6 | 0.96 ± 1.09 | 6.8 ± 1.8 | 7.2 ± 5.3 | 147 (75.4) | 105 (53.8) | 38 (19.5) | 18 (9.2) | 164 (84.1) | 31 (15.9) | 51.1 | 24.8 | 17.9 | 3.1 ± 1.4 | 55.6 |
| PPI non-treated N = 261 | 68.4 ± 11.1 | .001 | .060 | 21 (8.0) | 110 (42.1) | 73 (28.0) | 57 (21.8) | 1.4 ± 1.9 | 81.4 ± 19.2 | 3.7 ± 0.6 | 0.92 ± 0.79 | 6.2 ± 1.4 | 5.9 ± 4.6 | 137 (52.5) | 94 (36.0) | 42 (16.1) | 7 (2.7) | 174 (66.7) | 87 (33.3) | 56.4 | 14.8 | 4.6 | 3.2 ± 1.4 | 62.3 |

\( \chi^2 = .001 \), model for end-stage liver disease, PPI = proton pump inhibitor, SD = standard deviation.
Table 3

PPI treated and non-treated using a propensity score matching analysis with adjusted factors.

| Groups | PPI treated N = 120 | PPI non-treated N = 120 | P value by Wilcoxon signed-rank sum or Fisher exact test |
|--------|----------------------|------------------------|------------------------------------------------------|
| Age, yrs (mean ± SD) | 67.5 ± 10.3 | 68.4 ± 10.9 | .542 |
| Gender, n (%) | | | 1.000 |
| Males | 73 (60.8) | 73 (60.8) | | |
| Females | 47 (39.2) | 47 (39.2) | | |
| Background hepatitis, n (%) | | | .313 |
| Hepatitis B | 11 (9.2) | 8 (6.7) | |
| Hepatitis C | 32 (26.7) | 45 (37.5) | |
| Alcoholic hepatitis | 43 (35.8) | 40 (33.3) | |
| Others | 34 (28.3) | 27 (22.5) | |
| Total bilirubin, mg/dL | 1.5 ± 1.8 | 1.4 ± 1.5 | .184 |
| Prothrombin time, % | 75.1 ± 18.8 | 79.1 ± 21.2 | .118 |
| Albumin, g/dL | 3.6 ± 0.7 | 3.6 ± 0.7 | .317 |
| Creatinine, mg/dL | 1.06 ± 1.31 | 1.02 ± 1.11 | .911 |
| Child-Pugh Score | 6.5 ± 1.7 | 6.5 ± 1.5 | .912 |
| MELD score | 7.6 ± 5.8 | 6.5 ± 5.1 | .073 |
| Agents for LC complications, n (%) | 89 (74.2) | 77 (64.2) | .093 |
| Loop diuretics, n (%) | 62 (51.7) | 55 (45.8) | .366 |
| Synthetic disaccharides, n (%) | 23 (19.2) | 28 (23.3) | .430 |
| Oral poorly absorbable antibiotics, n (%) | 10 (8.3) | 6 (5.0) | .301 |
| LC statement, n (%) | | | .739 |
| Decompensated | 97 (80.8) | 99 (82.5) | | |
| Compensated | 23 (19.2) | 21 (17.5) | | |
| 5-year incidence rate of HCC, % | 48.5 | 56.8 | .840 |
| 5-year incidence rate of HE, % | 25.1 | 12.3 | .032 |
| 5-year incidence rate of GI bleeding, % | 7.7 | 10.1 | .721 |
| Observation period, yrs (mean ± SD) | 3.0 ± 1.4 | 3.1 ± 1.4 | .640 |
| 5-year survival rate, % | 52.4 | 54.5 | .676 |

GI = gastrointestinal, HCC = hepatocellular carcinoma, HE = hepatic encephalopathy, LC = liver cirrhosis, MELD = model for end-stage liver disease, PPI = proton pump inhibitor, SD = standard deviation.

Fig. 2c). Patients were divided according to the presence of HCC to investigate the relationship between PPIs and prognosis. The prognoses of LC patients both with and without HCC were no worse in the PPI-treated group than in the non-treated group (with HCC: P = .427; HR, 0.796; 95% CI, 0.453–1.395; Fig. 2d, without HCC: P = .090; HR, 1.968; 95% CI, 0.905–4.093; Fig. 2e).

4. Discussion

Our multi-center retrospective study has shown that there is a potential risk of increased HE occurrence associated with frequent use of PPIs and these should therefore only be administered with careful consideration of their necessity on a case-by-case basis, especially for the preventive use.

It has been reported that PPIs may facilitate oral bacterial translocation into the small intestine by suppressing gastric acid production,[14] and worsening dysbiosis via small intestine bacterial overgrowth, thereby increasing the incidence of HE. Comparison of microbiota in PPI-treated and non-treated patients indicated that the change caused by PPIs is similar to that caused by LC progression.[15] PPIs may therefore progress liver dysfunction by changing gut microbiota. Few reports have shown the clinical association between PPIs and HE and the results regarding this association have been inconsistent (Table 4).[16–24] Meta-analysis of these reports appears to demonstrate a positive relationship indicating that PPI-treatment may increase the risk of HE.[25–27] Furthermore, other reports comparing LC patients with and without HE concluded that PPI administration is an independent factor associated with HE.[28,29] Conversely, several reports suggest that it is premature to decide whether PPIs induce the development of HE in cirrhotic patients[11,12] because of the difference in background adjustment. In our cohort, the backgrounds of PPI-treated and non-treated patients were significantly different in terms of liver function and onset of GI bleeding. In fact, the PPI-treated group in our study showed poorer hepatic functions (evidenced by worse Child-Pugh scores and MELD scores) and had higher chances of GI bleeding events treated with PPIs. Therefore, a propensity score matching analysis was performed to aid in these comparisons and to determine the effects of PPI on HE and prognosis. Based on these meticulous analyses, the associations between the type of PPIs and HE in our findings were similar to those of previous reports.[20,22] Our results further implied an association between PPIs and the levels in hepatocytes of cytochrome P450, which delays metabolism of certain PPIs in cytochrome P450, which delays metabolism of certain PPIs in patients with LC, however this might be related to the type of PPI administered.[22] Although some reports indicate no significant associations between PPI administration and LC prognosis,[36] it is clear, that complications of HE and GI bleeding are associated with worse prognoses in LC patients. By matching the factors of GI bleeding, liver function, and HCC incidence, our study demonstrated that similar to these previous reports PPI administration increased the risk of HE occurrence.[23–27] Interestingly however, we observed no effect of PPI administration on patient’s prognoses as de Vos M, et al reported.[16] This
study demonstrated for the first time that long-term PPI administration is related to a higher incidence of HE, but did not affect the overall prognosis of a Japanese patient cohort. Notably, a systematic review has also indicated that the long-term administration of PPIs does not prevent GI bleeding,[37] therefore, it is important to assess the benefit of PPIs for patients with LC on a case-by-case basis, taking the endoscopic findings in GI, bleeding tendency, alcohol abuse, and other factors into consideration.

This study had some limitations. Firstly, factors that directly induced HE including the hypovolemia, constipation, and administration of benzodiazepines[6] and prior history of HE was not assessed, although there were no significant differences between the groups regarding the oral administration of poorly absorbable antibiotics. Secondly, bias with case selection could not be excluded as the onset of GI bleeding was higher in PPI-treated patients and this could be a precipitator for development of HE. Data were gathered from patients with clinically diagnosed LC, and the frequency of the compensated LC cases was lower than that of the decompensated cases. Therefore, distinguishing chronic hepatitis from LC was difficult, and some LC cases might have been excluded. In addition, the difference of the prognosis of LC between ethnics[38] and the pharmacokinetic drug interaction with the activity of PPI needs to be considered in the future study.[39]

In conclusion, this multicenter retrospective study showed that PPI treatment might be associated with increased HE occurrence but did not worsen the prognosis of PPI-treated patients with LC (Graphical abstract). Considering the relatively low preventive effect of PPI on GI bleeding in liver cirrhotic cases, it is recommended that PPIs should only be administered with careful consideration. Further research is needed including the develop-

---

Figure 2. Cumulative incidence plots for PPI treated and non-treated patients using propensity-score matching analysis with adjusted factors. (A) The incidence of hepatic encephalopathy among the PPI-treated and non-treated patients. (B) Effect of rabeprazole on hepatic encephalopathy. (C) Overall survival of liver cirrhosis patients with or without PPI treatment. (D, E) After dividing patients according to the presence of HCC, there was no difference in the prognoses of patients with (D) and without (E) HCC among either the PPI-treated or the PPI non-treated groups. PPI = proton pump inhibitor, HCC = hepatocellular carcinoma.
Table 4

Summary of the reported studies.

| Author          | Year     | Type            | Number of cases (PPI treated / non-treated) | Age (average)   | GI bleeding (%) | HCC (%) | LC (%) | Men (%) | Effect of PPI on HE |
|-----------------|----------|-----------------|--------------------------------------------|----------------|----------------|---------|--------|---------|---------------------|
| Terg K17        | 2015     | Prospective     | 165 / 219                                  | 3 mo           | 57 / 57        | 68 / 77 | 100 / 100 | NA      | Negative            |
| Dam G18         | 2016     | Retrospective   | 340 / 525                                  | 30 mo          | 58 / 57        | 68 / 69 | 100 / 100 | NA      | Negative            |
| Huang KW19      | 2016     | Retrospective   | 1870 / 1190                                | 13 yrs         | 54 / 53        | 74 / 81 | 74 / 55 | 74 / 74 | Positive            |
| Cole HL20       | 2016     | Retrospective   | 114 / 92                                   | 2 yrs          | 57 / 56        | 74 / 69 | 63 / 65 | 63 / 54 | Positive            |
| Tsai CF21       | 2017     | Retrospective   | 2332                                       | 13 yrs         | 53             | 74      | NA      | NA      | Negative            |
| Schiavon LL22   | 2017     | Prospective     | 93 / 98                                    | 2 yrs          | 57 / 52        | 63 / 73 | 63 / 67 | 63 / 74 | Positive            |
| Hung TP23       | 2017     | Retrospective   | 1004 / 4016                                | 1 yrs          | 57 / 52        | 67 / 63 | 69 / 67 | 64 / 67 | Positive            |
| Fasullo M24     | 2019     | Retrospective   | 7526                                       | 12 / 19         | 57 / 73        | 63 / 73 | 63 / 67 | 63 / 74 | Positive            |
| Nardelli S13    | 2019     | Prospective     | 1851 / 726                                 | 13 yrs         | 57 / 52        | 63 / 73 | 63 / 67 | 63 / 74 | Positive            |

* = significantly different, GI = gastrointestinal, HCC = hepatocellular carcinoma, HE = hepatic encephalopathy, LC = liver cirrhosis, NA = not available, PPI = proton pump inhibitor.

References

[1] D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217–31.
[2] Wijdicks EF. Hepatic encephalopathy. N Engl J Med 2016;375:1660–70.
[3] Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in hepatic encephalopathy. Gastroenterol Res Pract 2012;2012:642108.
[4] Funakoshi N, Duny Y, Valats JC, et al. Meta-analysis: beta-blockers versus banding ligation for primary prophylaxis of esophageal variceal bleeding. Ann Hepatol 2012;11:369–83.

Acknowledgments

We would like to thank all the gastroenterologists and hepatologists at Nagaoka Red Cross Hospital, Niigata Central Prefectural Hospital, Niigata City General Hospital, and Niigata University Hospital. They also thank Enago for the critical reading of the manuscript and English language review.

Author contributions

Conceptualization: Akira Sakamaki, Kenya Kamimura.

Data curation: Akira Sakamaki, Takeshi Yokoo, Akihiko Osaki, Seiichi Yoshikawa, Yoshihisa Arao, Toru Setsu, Hirouter Kamimura, Nobuo Waguri, Manabu Takeuchi, Kazuhiro Funakoshi.

Formal analysis: Akira Sakamaki, Kenya Kamimura, Takeshi Yokoo, Akihiko Osaki, Seiichi Yoshikawa, Yoshihisa Arao, Toru Setsu, Hirouter Kamimura, Nobuo Waguri, Manabu Takeuchi, Kazuhiro Funakoshi, Shuji Terai.

Supervision: Shuji Terai.

Validation: Toru Setsu, Shuji Terai.

Writing – original draft: Akira Sakamaki, Kenya Kamimura.

Writing – review & editing: Akira Sakamaki, Kenya Kamimura, Takeshi Yokoo, Akihiko Osaki, Yoshihisa Arao, Toru Setsu, Hirouter Kamimura, Shuji Terai.

The potential role of intestinal flora in determining which patients will benefit from treatment.

References

[1] D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217–31.
[2] Wijdicks EF. Hepatic encephalopathy. N Engl J Med 2016;375:1660–70.
[3] Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in hepatic encephalopathy. Gastroenterol Res Pract 2012;2012:642108.
[4] Funakoshi N, Duny Y, Valats JC, et al. Meta-analysis: beta-blockers versus banding ligation for primary prophylaxis of esophageal variceal bleeding. Ann Hepatol 2012;11:369–83.
[13] Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014;60:715–35.

[14] Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014;513:59–64.

[15] Yamamoto K, Ishigami M, Honda T, et al. Influence of proton pump inhibitors on microbiota in chronic liver disease patients. Hepatol Int 2019;13:234–44.

[16] Terg R, Casiato P, Garbe C, et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. J Hepatol 2015;62:1036–60.

[17] Dam G, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology 2016;64:1265–72.

[18] Huang KW, Kuan YC, Luo JC, Lin CL, Liang JA, Kao CH. Impact of long-term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosis. Eur J Intern Med 2016;32:91–5.

[19] Cole HL, Pennycook S, Hayes PC. The impact of proton pump inhibitor therapy on patients with liver disease. Aliment Pharmacol Ther 2016;44:1213–23.

[20] Tsai CF, Chen MH, Wang YP, et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study. Gastroenterology 2017;152:134–41.

[21] Schiavon LL, Silva TE, Fischer J, Narciso-Schiavon JL. Letter: proton pump inhibitors and prognosis of cirrhosis - searching for the balance point. Aliment Pharmacol Ther 2017;45:378–9.

[22] Hung TH, Lee HF, Tseng CW, Tsai CC, Tsai CC. Effect of proton pump inhibitors in hospitalization on mortality of patients with hepatic encephalopathy and cirrhosis but no active gastrointestinal bleeding. Clin Res Hepatol Gastroenterol 2018;42:353–9.

[23] Fasullo M, Rau P, Liu DQ, et al. Proton pump inhibitors increase the severity of hepatic encephalopathy in cirrhotic patients. World J Hepatol 2019;11:522–30.

[24] Nardelli S, Gioia S, Ridola L, Farcomeni A, Merli M, Riggio O. Proton pump inhibitors are associated with minimal and overt hepatic encephalopathy and increased mortality in patients with cirrhosis. Hepatology 2019;70:640–9.

[25] Tantai XX, Yang LB, Wei ZC, et al. Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis. World J Gastroenterol 2019;25:2683–98.

[26] Ma YJ, Cao ZX, Li Y, Feng SY. Proton pump inhibitor use increases hepatic encephalopathy risk: a systematic review and meta-analysis. World J Gastroenterol 2019;25:2675–82.

[27] Shi D, Zhou Z, Dai Y, Pan X, Cao Q. Proton pump inhibitor therapy and hepatic encephalopathy risk in cirrhotic patients: a systematic review with meta-analysis. Clin Drug Investig 2019;39:847–56.

[28] Kuan YC, Huang KW, Lin CL, Luo JC, Kao CH. Short-term proton pump inhibitor use and hepatic encephalopathy risk in patients with decompensated cirrhosis. J Clin Med 2019;8:1108.

[29] Zhu J, Qi X, Yu H, et al. Association of proton pump inhibitors with the risk of hepatic encephalopathy during hospitalization for liver cirrhosis. United European Gastroenterol J 2018;61:1179–87.

[30] Pan Z, Wu XJ, Li JS, Liu FN, Li WS, Han JM. Functional hepatic flow in patients with cirrhosis. World J Gastroenterol 2004;10:915–8.

[31] Andersson T, Miners JO, Veronese ME, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 1994;37:597–604.

[32] Katsuki H, Nakamura C, Arimori K, Fujiiyama S, Nakano M. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur J Clin Pharmacol 1997;52:391–6.

[33] Yasuda S, Ohnishi A, Ogawa T, et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther 1994;32:466–73.

[34] VandenBranden M, Ring BJ, Binley SN, Wrighton SA. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 1996;6:81–91.

[35] Dultz G, Piper A, Zeuzem S, Kronenberg B, Waidmann O. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment Pharmacol Ther 2015;41:459–66.

[36] De Vos M, De Vroe B, Garcia BG, et al. Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Liver Int 2013;33:1316–23.

[37] Lo EA, Wilby KJ, Ensom MH. Use of proton pump inhibitors in the management of gastroesophageal varices: a systematic review. Ann Pharmacother 2015;49:207–19.

[38] Ebadi M, Rhanji RA, Montano-Loza AJ. Ethnic disparities in the prognosis of cirrhosis. Transplantation 2019;103:2462–3.

[39] Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf 2014;37:201–11.